Dover, DE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (ATON) (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics ...
Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results